You are here

cancer gentics project 3 excerpt 4

Submitted by jdantonio on Thu, 05/04/2017 - 17:47

For the selection of our T-cells that possess endogenous neoantigen receptors we first harvest T-cells by taking blood samples from our patient. The Cells would then be separated from the plasma and the neoantigen cytotoxic T-cells would be selected out by using autologous DC cells that have been loaded with the protein epitome of the neoantigens which we have identified (Yee et al 2002). We will be following the standard procedure for adoptive T-cell generation as described in Yee et al 1999(Yee et al 1999). In short the T-cells are separated and cloned, creating identical clone lines, then screened by testing them for their ability to bind to antigen loaded dendritic cells which are placed in a set of loaded wells for testing. The population of T-cells that are found to bind to the neoantigen are then put through a chromium lystic test. where in the TILs are put on a plate with harvested tumor cells that present the target neoantigen and have been loaded with chromium, the lysing of these cells causes the release of chromium and can be used to test whether the antigen binding T-cells are cytotoxic (Yee et al 2002).  The antigen binding cytotoxic  T-cells will then be raised in culture containing IL-2 and anti CD3-antibodies which activated the growth and proliferation of T-cells, this will be done in 14 day cycles.(Yee et al 2002) We will perform theses screening tests to find a population of cells that can bind to the neoantigens we experimentally derived, we would hope to find cell lines cable of binding to about 10 of the 20 most common of our neoantigens.We will also give preference to those T-cells capable of binding neoantigens caused by driver mutations, mutations that are critical to cancer progression(Stratton et al 2009). With this we will have 10,or more hopefully, T-cell lines that can bind to our tumor and initiate cell death. The use of multiple adoptive cell lines will help to prevent the cancer from become resistant to our treatment, as one single mutation, or even a few, would not be enough for the tumor to evade treatment. Finally we will further the effectiveness by knocking out the T-cell suppression CTLA-4 receptor and the T-cell death initiating PDL-1 receptor by CRISPR knockout as described in detail later in the project (Albain et al 2015).

 

Ablain J, Durand EM, Yang S,  Zhou Y,  Zon LI. 2015. A CRISPR/Cas9 Vector System for

Tissue-Specific Gene Disruption in Zebrafish. Developmental Cell 32(6): 756–764.

Sciencedirect.<http://www.sciencedirect.com/science/article/pii/S1534580715000751>.

Accessed 2017 May 1.

 

Stratton MR,Campbell PJ, Futreal PA. 2009. The cancer genome. Nature 458: 719-724.

<http://www.nature.com/nature/journal/v458/n7239/full/nature07943.html>. Accessed

2017 may 1.

 

Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, and Greenberg PD. 2002.Adoptive

T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients

with metastatic melanoma: In vivo persistence, migration, and antitumor effect of

transferred T cells. Proceedings of the National Academy of Sciences 99(25):

16168–16173. <http://www.pnas.org/content/99/25/16168.full.pdf> Accessed 2017 April

30



Yee C,  Savage PA,  Lee PP, Davis MM, and Greenberg PD. 1999.Isolation of High Avidity

Melanoma-Reactive CTL from Heterogeneous Populations Using Peptide-MHC

Tetramers. The Journal of Immunology 162 (4) 2227-2234. <http://

www.jimmunol.org/content/162/4/2227?ijkey=5e73920a74aaa8e458988ce6c5acc1d1f2f9

ef72&keytype2=tf_ipsecsha>. Accessed 2017 April 30.

Post: